

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc. **長風藥業股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT **EXPANSION OF INDICATIONS OF ICF001 FOLLOWING RECEIPT OF** **IMPLIED CLINICAL TRIAL APPROVALS FROM THE NMPA**

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest research and development progress of the Group.

INTRODUCTION

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that ICF001, a self-developed long-acting inhaled dry powder candidate (the “**Product**”), has obtained implied clinical trial approvals from the National Medical Products Administration of the People's Republic of China (the “**NMPA**”) to conduct clinical trials in interstitial lung disease, namely idiopathic pulmonary fibrosis (“**IPF**”) and progressive pulmonary fibrosis (“**PPF**”).

These approvals follow the NMPA's implied clinical trial approvals obtained in March 2026 for the Product to conduct clinical trials in pulmonary arterial hypertension (“**PAH**”) and pulmonary hypertension associated with interstitial lung disease (“**PH-ILD**”). The Product is now cleared to enter clinical studies across four indications spanning pulmonary vascular disease and progressive fibrosing lung disease.

STRATEGIC SIGNIFICANCE

The four indications of the Product are expected to be developed from a common molecule, formulation, device and clinical pharmacology platform, which the Company believes may improve development efficiency. PAH and PH-ILD are directed at pulmonary vascular resistance, exercise capacity and right heart burden, while IPF and PPF provide a pathway into progressive fibrosing lung disease.

Based on the Company's preclinical and formulation work to date, the current design objective is to split the daily dose into two administrations (that is, twice-daily dosing), with the intention of maintaining coverage throughout the dosing interval while moderating peak exposure and allowing flexibility in dose adjustment or temporary interruption.

In China, treatment of PAH has moved towards combination therapy across multiple mechanisms, but the availability of inhaled and long-acting prodrug products remains limited, and unmet clinical need persists across PH-ILD, IPF and PPF. If the Product completes clinical development successfully and obtains marketing approval, the Company intends to draw on its domestic research and development, inhalation manufacturing and commercial capabilities to support patient access.

The Company plans to conduct Phase I trials in China and, subject to obtaining the necessary approvals from the relevant overseas regulatory authorities, overseas. The Company currently intends to explore possible global multi-centre development, regional licensing, co-development or other forms of collaboration in the future. The Company will assess potential opportunities having regard to the maturity of the clinical data.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. There is no assurance that the approval of clinical trials will result in the achievement of successful clinical results, the grant of marketing approval or the realization of commercialization. Given such risks and uncertainties, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities – from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms – the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening global presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board

CF PharmTech, Inc.

長風藥業股份有限公司

Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, August 24, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi, Ms. ZHU Yuyu and Ms. ZHANG Jingjing as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.